• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Clinical Impact of Metastatic Lymph Node Size on Therapeutic Effect and Prognosis in Patients with Esophageal Squamous Cell Carcinoma Who Underwent Preoperative Chemotherapy Followed by Esophagectomy.

作者信息

Sugimura Keijiro, Miyata Hiroshi, Kanemura Takashi, Takeoka Tomohira, Sugase Takahito, Yamamoto Masaaki, Shinnno Naoki, Hara Hisashi, Omori Takeshi, Motoori Masaaki, Ohue Masayuki, Yano Masahiko

机构信息

Department of Digestive Surgery, Osaka International Cancer Institute, Osaka, Japan.

Department of Surgery, Kansai Rosai Hospital, Amagasaki City, Hyogo, Japan.

出版信息

Ann Surg Oncol. 2023 Jul;30(7):4203-4204. doi: 10.1245/s10434-023-13456-w. Epub 2023 Apr 8.

DOI:10.1245/s10434-023-13456-w
PMID:37029864
Abstract
摘要

相似文献

1
ASO Author Reflections: Clinical Impact of Metastatic Lymph Node Size on Therapeutic Effect and Prognosis in Patients with Esophageal Squamous Cell Carcinoma Who Underwent Preoperative Chemotherapy Followed by Esophagectomy.
Ann Surg Oncol. 2023 Jul;30(7):4203-4204. doi: 10.1245/s10434-023-13456-w. Epub 2023 Apr 8.
2
Clinical Impact of Metastatic Lymph Node Size on Therapeutic Effect and Prognosis in Patients with Esophageal Squamous Cell Carcinoma Who Underwent Preoperative Chemotherapy Followed by Esophagectomy.术前化疗联合食管癌切除术治疗后转移性淋巴结大小对食管鳞癌患者治疗效果及预后的临床影响。
Ann Surg Oncol. 2023 Jul;30(7):4193-4202. doi: 10.1245/s10434-023-13393-8. Epub 2023 Apr 3.
3
ASO Author Reflections: The Lymph Node Ratio is an Independent Prognostic Factor in Esophageal Squamous Cell Carcinoma After Minimally Invasive Esophagectomy.ASO作者反思：淋巴结比率是微创食管切除术后食管鳞状细胞癌的独立预后因素。
Ann Surg Oncol. 2021 Aug;28(8):4529. doi: 10.1245/s10434-020-09452-z. Epub 2021 Jan 5.
4
ASO Author Reflections: Using Efficacy Index to Clarify the Clinical Value of Each Lymph Node Station for Esophageal Squamous Cell Carcinoma.美国外科医师学会（ASO）作者反思：利用疗效指数阐明食管鳞状细胞癌各淋巴结站的临床价值
Ann Surg Oncol. 2023 Sep;30(9):5866-5867. doi: 10.1245/s10434-023-13739-2. Epub 2023 Jun 15.
5
ASO Author Reflections: Radiomics-Based Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma.ASO作者反思：基于放射组学预测食管鳞状细胞癌个体淋巴结转移状态
Ann Surg Oncol. 2022 Dec;29(13):8127-8128. doi: 10.1245/s10434-022-12230-8. Epub 2022 Aug 6.
6
ASO Author Reflections: Supraclavicular Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma.ASO作者反思：食管鳞状细胞癌锁骨上淋巴结转移
Ann Surg Oncol. 2024 Mar;31(3):1583-1584. doi: 10.1245/s10434-023-14703-w. Epub 2024 Jan 8.
7
Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma.术前化疗对食管鳞状细胞癌转移性淋巴结的影响。
Dis Esophagus. 2002;15(3):226-31. doi: 10.1046/j.1442-2050.2002.00260.x.
8
ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy.ASO作者反思：胸段食管鳞状细胞癌患者食管切除术后的预后分层及辅助治疗的价值
Ann Surg Oncol. 2019 Dec;26(Suppl 3):802-803. doi: 10.1245/s10434-019-07728-7. Epub 2019 Oct 25.
9
ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.《血管外科学年鉴》作者反思：探索新辅助放化疗后食管鳞状细胞癌患者淋巴结评估的最佳参数
Ann Surg Oncol. 2024 Feb;31(2):899-900. doi: 10.1245/s10434-023-14189-6. Epub 2023 Nov 25.
10
ASO Author Reflections: Impact of Metastatic Lymph Nodes on Survival of Patients with pN1-Category Esophageal Squamous Cell Carcinoma.ASO作者反思：转移性淋巴结对pN1期食管鳞状细胞癌患者生存的影响
Ann Surg Oncol. 2024 Jun;31(6):3850-3851. doi: 10.1245/s10434-024-15047-9. Epub 2024 Mar 11.

本文引用的文献

1
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.纳武利尤单抗联合治疗晚期食管鳞癌。
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
2
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌（KEYNOTE-590）：一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
3
Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Results.
多中心随机 2 期临床试验比较放化疗和多西他赛联合 5-氟尿嘧啶和顺铂化疗作为临床 T4b 食管癌患者后续转化手术的初始诱导治疗：短期结果。
Ann Surg. 2021 Dec 1;274(6):e465-e472. doi: 10.1097/SLA.0000000000004564.